Researchers are exploring the use of zwitterionic ionizable lipids in lipid nanoparticles (LNPs) to target specific organs, such as the spleen, for mRNA translation. This involves replacing traditional components like cholesterol and PEGylated lipids with these new lipids. Studies are investigating the design principles, targeting strategies, and potential clinical applications of these reformulated LNPs for nucleic acid therapeutics.